Market Market Market

Market Quick Take - December 23, 2021

Macro 6 minutes to read
Saxo Strategy Team

Summary:  New studies indicating less Omicron hospitalization from Scotland, South Africa and Denmark lifted market together with good Conference Board Consumer confidence data yesterday. It is still nervous trading and illiquidity continues. The revised Q3 data upped both GDP and the price indicators. GDPQ3 now at 2.3% while Price deflator is at 6%. Today's most important event is the US PCE inflation report for November.


What is our trading focus?

Nasdaq 100 (USNAS100.I) and S&P 500 (US500.I) - US equities continued their momentum yesterday with Nasdaq 100 futures hitting 16,170 up 1.2% on more positive Omicron studies on its hospitalization rate compared to the Delta variant.

Energy crisis (OIL:xmil) - US IEA reported higher than expected draws yesterday and combined with the positive Omicron studies crude oil pushed higher yesterday together with equities. The German Baseload Forward 1-year contract closed at a new all-time high yesterday at €315/MWh but is coming a bit off this morning in Europe despite an outlook for colder weather in Europe.

USDJPY - the cross broke above the recent local resistance level at 114.26 in yesterday’s session before retreating, but this morning the cross is following the risk-on sentiment higher sitting at this important resistance level.

Gold (XAUUSD) - just as the market was preparing for more sell-off with gold starting yesterday’s session pushing below the 200-day moving average, the stronger EURUSD helped gold turn around pushing through all key moving averages. Gold is trading around 1,806 this morning with the 1,814 level in sight (the recent highs) should EURUSD extending its momentum.

US Treasuries (SHY, IEF, TLT). The US 10-year yield is settling just below the 1.5% level before the crucial PCE inflation report for November out later today. If the PCE inflation figure surprises to the upside, then we could see the 10-year yield push firmly above the 1.5% level.

USDTRY – the cross is pushing lower in a short-term victory lap for the Turkish government that has implemented several unusual measures to deal with inflation, currency swings, and economic problems. USDTRY is trading 11.67 in early European trading with the 50-day moving average sitting at 11.51 which the cross has not been below since mid-September.

What is going on?

JD.com shares down 8% on Tencent divestment. Normally this time of the year is quiet in the markets, but Tencent put out a surprise today announcing that they are divesting their JD.com investment and issuing a special dividend of $16bn. The divestment should be seen as a response to the ongoing technology crackdown with the large technology companies beginning to disentangle themselves from each other.

Scottish study shows Omicron has two-thirds hospitalization risk compared to Delta. Another study showing signs that Omicron is less virulent, but in the short-term health authorities are saying that less virulent multiplied by higher contagiousness equal more pressure on hospitals. But looking beyond the next couple of weeks the news flow could positive supporting risk assets.

Amazon’s cloud business (AWS) is targeted by FTC. AWS has always been the golden egg for Amazon delivering most of its profits and is the definitive market leader in cloud infrastructure. The question has always been to what degree AWS is taking advantage of this position against customers and to what extent the high profit margin in AWS is used to subsidize the e-commerce business helping it keeping prices incredibly low hurting other retailers with no cloud business.

Pfizer’s Covid pill gets FDA approval. The US FDA granted emergency use authorization for Pfizer’s Covid pill, which is the first antiviral drug against the virus for at-home use. Pfizer’s shares rose 1% to $59.55.

Ryanair cuts fiscal year earnings guidance. Underscores the uncertainty and negative impact from Omicron in the medium-term. The news will likely impact the entire travel and leisure segment in Europe in today’s session.

What are we watching next?

It’s already Christmas in the markets. Thin liquidity and mainly event driven moves over the course of the day. We expect these conditions to continue this and next week as we enter the final week of the year. The year has been mixed and as such some rotation towards defensive will likely happen. We have full focus on energy prices as a culprit for more inflationary pressure.

PCE inflation report on Thursday. This is the key event this week and today’s PCE inflation report will likely show that inflationary pressures persisted throughout November and supporting the FOMC decision last week to end the wording “transitory inflation” and signaling faster tapering and a path to three rate hikes in 2022.

Earnings Watch – no earnings this week and will stay light until the Q4 earnings season starts in mid-January.

Economic calendar highlights for today (times GMT)

0900 – Italy Consumer Confidence Dec

1330 – US Initial and Continuing Claims

1330 – US Personal Spending Dec

1330 – US PCE Core Deflator Nov (The Fed’s measure of US inflation)

1330 – US Durable Goods Orders Nov

1500 – US New Home Sales

 

Follow SaxoStrats on the daily Saxo Markets Call on your favorite podcast app:

Apple Sportify Soundcloud Stitcher

Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.